Published in Telemedicine Week, October 16th, 2007
This trend article about Fukuoka University, Japan, is an immediate alert from NewsRx to identify developing directions of research.
Study 1: Fresh data on angiotensins are presented in the report "Do all angiotensin II type 1 receptor blockers have the same beneficial effects. Angiotensin II type 1 (AT(1)) receptor blockers (ARBs) are highly selective for the AT(1) receptor, which is a member of the G protein-coupled receptor superfamily (GPCRs), and block the diverse effects (hypertension, hypertrophy, heart failure, proteinuria etc.) of angiotensin II. Many ARBs are in clinical use...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Telemedicine Week